15-keto-Prostaglandin E2

15-keto-Prostaglandin E2 is an endogenous metabolite. 15-keto-Prostaglandin E2 inhibits STAT3 activation by binding to its Cys259 residue. 15-keto-Prostaglandin E2 can bind and stabilize EP2 and EP4 receptor. 15-keto-Prostaglandin E2 inhibits breast cancer cell growth and progression. 15-keto-Prostaglandin E2 activates PPAR-γ and promotes fungal growth[1][2][3].

Product Specifications

CAS Number

[26441-05-4]

Product Name Alternative

15-keto-PGE2

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Endogenous Metabolite; PPAR; Prostaglandin Receptor; STAT

Type

Natural Products

Related Pathways

Cell Cycle/DNA Damage; GPCR/G Protein; JAK/STAT Signaling; Metabolic Enzyme/Protease; Stem Cell/Wnt; Vitamin D Related/Nuclear Receptor

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/15-Keto-prostaglandin_E2.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

CCCCCC(/C=C/[C@@H]1[C@H](C(C[C@H]1O)=O)C/C=C\CCCC(O)=O)=O

Molecular Formula

C20H30O5

Molecular Weight

350.45

Precautions

H302, H315, H319, H335

References & Citations

[1]Lee EJ, et al. 15-Keto prostaglandin E2 suppresses STAT3 signaling and inhibits breast cancer cell growth and progression. Redox Biol. 2019 May;23:101175.|[2]Kourpa A, et al. 15-keto-Prostaglandin E2 exhibits bioactive role by modulating glomerular cytoarchitecture through EP2/EP4 receptors. Life Sci. 2022 Dec 1;310:121114.|[3]Evans RJ, et al. 15-keto-prostaglandin E2 activates host peroxisome proliferator-activated receptor gamma (PPAR-γ) to promote Cryptococcus neoformans growth during infection. PLoS Pathog. 2019 Mar 28;15 (3) :e1007597.